JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Effects of depression and quality of life in diabetic patients.

Krrish Sethi
Student
Amity University

Abstract

Type 2 diabetes is a chronic metabolic condition affecting millions of individuals worldwide. Depression, on the other hand, is a frequent mental health disorder that affects many people, including diabetics. Depression and diabetes are frequently connected, and the presence of both illnesses can contribute to a decline in life quality for diabetic patients. This study article will look at the influence of depression on diabetes care, especially how depression impacts medication adherence and lifestyle changes in diabetic individuals. In addition, the research delves into the psychological and emotional issues that diabetes patients confront when they also have depression. Finally, the literature review considers potential strategies to address the influence of depression on the decline of life in diabetes patients. By studying these difficulties, this study article hopes to get a better knowledge of how depression impacts diabetes patients and how healthcare practitioners may better treat this issue to enhance patient outcomes.

INTRODUCTION

Diabetes mellitus, often referred to simply as diabetes, is a chronic health condition that affects how your body uses blood sugar (glucose). Glucose is crucial for providing energy to cells and is the primary source of energy for your brain. Diabetes occurs when your body either doesn't produce enough insulin (a hormone that helps glucose enter cells) or doesn't effectively use the insulin it produces. This leads to elevated blood sugar levels, which can cause various health complications over time.

Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease characterized by the body's inability to produce insulin. Without proper insulin production, the body is unable to regulate blood sugar levels, leading to a host of physical and psychological complications. One psychological complication commonly associated with T1DM is depression. Depression is a mental health disorder that affects mood, thoughts, and behaviour. Individuals with T1DM are at a higher risk of developing depression compared to the general population. According to several studies, the incidence of depression is higher in individuals with T1DM compared to those without diabetes. Depression in individuals with T1DM can have a significant impact on their overall well-being and quality of life.

Depression can worsen the symptoms of T1DM and impair glycaemic control, leading to further complications.

Type-2 Diabetes Mellitus (T2DM) has been diagnosed as a persistent impairment in the body's capacity to metabolise glucose effectively. Extensive research into human biochemical complexity has shown that glucose metabolism plays a crucial role in maintaining the correct physiological balance of lipids, amino acids, and different carbohydrate metabolic chains. Thus, long-term T2DM can result in life-threatening and severe neurodegenerative consequences (Alzheimer's and Parkinson's), diabetic glaucoma, non-alcoholic fatty liver, cardiovascular issues, hearing impairments, and so on. T2DM is defined by insulin insufficiency, hyperglycemia, and insulin resistance. While the regulating enzymes of glucose metabolism have a net hyperglycemic impact, only insulin exhibits hypoglycemic action.

T2DM is also known as a beta-cell related insulin resistance syndrome, which is more common in adults but can sometimes develop at a younger age. Current T2DM diagnostic trends comprise measuring glucose levels beyond a threshold value of 7.0 mmol/l and 11.0 mmol/l during the fasting state, as well as about two hours later during the postprandial state, after consuming 75 g of glucose. At any given time, glucose concentration in human bodies may be calculated as the net glucose generation via endogenous pathways combined with insulin-mediated glucose utilisation for cellular

processes. However, insulin resistance in T2DM inhibits these insulin-mediated glucose metabolic pathways, resulting in beta cell malfunction.

For those with diabetes, the usual blood sugar range is less than 180 mg/dL after meals and 70–130 mg/dL before to meals.

Other types include:

Gestational diabetes: This type occurs during pregnancy when the body cannot produce enough insulin to meet the increased demand. It usually resolves after childbirth, but it increases the risk of developing type 2 diabetes later in life.

Other specific types: There are also other specific types of diabetes, such as monogenic diabetes (caused by a genetic mutation) and secondary diabetes (resulting from other medical conditions or medications).

Diabetes mellitus is characterized by hyperglycemia, which means high levels of glucose (sugar) in the blood. It's a chronic condition, meaning it lasts for a long time and requires ongoing management. Additionally, diabetes is progressive, meaning it tends to worsen over time if not properly controlled. Over the years, uncontrolled diabetes can lead to various complications affecting different parts of the body, including the eyes, kidneys, nerves, heart, and blood vessels. Early diagnosis, proper treatment, and lifestyle management are crucial in managing diabetes effectively and preventing complications.

The daily insulin and glucose profiles show that, while type 2 diabetes patients have higher glucose levels, the insulin concentrations are not significantly different from the ones of healthy persons. The amount of glucose in the blood at any given time is determined by the net, the integrated balance in between rate(s) of glucose entry into the blood from endogenous glucose production and/or glucose absorption by the gut and a measure of glucose exit from the blood due to the various ways that glucose is used, including glycosuria above a plasma glucose concentration of approximately 10 mmol/L. Insulin has the potential to boost glucose uptake while decreasing endogenous glucose production.

Beta cell failure, in turn, prevents glucose transport to liver and muscle cells, resulting in elevated blood sugar levels and excessive fat breakdown.



Figure 1. Diabetes prevalence in adult population in the world.

Understanding the mechanisms that maintain normal glucose homeostasis during the postabsorptive and ingestion phases is crucial to understanding the pathophysiology of Type-2 Diabetes Mellitus.

The majority of glucose utilisation during post-absorptive states occurs in insulin-independent tissues, such as the encephalon, which utilises approximately 50% of glucose, and the splanchnic area, which utilises net 25% of glucose. Conversely, insulin-dependent tissues, such as skeletal muscles and adipose tissue, use the remaining 25% of glucose content in postprandial states.

Biochemical processes of gluconeogenesis and glycogenolysis have significant contributions to basal rates of hepatic glucose.

The discovery of insulin in the 1920s greatly expanded our knowledge of diabetes as a metabolic illness. For a long time, diabetes was thought to be a mono-hormonal condition characterised by an insufficient or excessive amount of insulin in the body. Insulin is a powerful hormone that inhibits endogenous glucose synthesis and stimulates the body's use of glucose. Recent research, however, has increased our understanding that the development of the T2DM phenotype as a whole is caused by the concurrent activities of additional glucoregulatory hormones in addition to insulin.

Keywords: Diabetes, insulin, depression.

QOL evaluation plays a crucial role in assessing the overall well-being and quality of life of diabetic patients. By measuring various aspects such as satisfaction with health, regular follow-up visits, and access to healthcare services, QOL evaluation provides valuable insights into the impact of diabetes on different areas of a patient's life. It helps healthcare providers and policymakers identify areas where interventions are needed to improve the quality of life for diabetic patients, such as promoting positive self-management behaviours and increasing awareness of diabetes and its specific risk factors. Additionally, QOL evaluation can help identify the presence of comorbidities and complications associated with diabetes that may further impact an individual's overall well-being and guide the development of integrated programs and interventions to address these issues.

Satisfaction with health, regular follow-up visits in a clinic, meeting a doctor at least monthly, and having diabetes were significantly associated with better quality of life. - Improvements on QoL can be achieved through different intervention programs by enhancing positive diabetes-related self- management behaviours. QOL evaluation helps healthcare providers understand the impact of diabetes on various aspects of a patient's life and identify areas for improvement. QOL evaluation is an essential tool in understanding and assessing the impact of diabetes on the overall well-being and quality of life of patients.

1 INSULIN GLUCOSE METABOLISM

The pancreatic endocrine system's islets of Langerhans, which are made up mostly of beta and alpha cells, respectively, release the hormones insulin and glucagon, which have the potency to control blood glucose levels. Glucagon mainly affects hepatocytes, or liver cells, where it stimulates the production of gluconeogenesis and glycogenolysis, raising blood glucose levels overall and causing a condition known as hyperglycemia. The peptide hormone insulin, on the other hand, is crucial in controlling glucose homeostasis. It has a hypoglycaemic action, which is different from glucagon's, since it promotes a large-scale inflow of glucose into adipose tissue and hepatocytes, therefore drastically decreasing blood glucose levels.

Normal physiological study of plasma glucose concentrations shows that the liver's process of breaking down glycogen (glycogenolysis), the body's production of glucose from lactate and amino acids (gluconeogenesis), intestinal absorption rates, and other processes are some of the sources of circulating glucose. Under 8–12 hours of fasting (during sleep cycles), the body produces glucose through a process called glycogenolysis, which is regulated by the hormone glucagon. The system's circulation of glucose is opened by this procedure. Prolonged fasting, defined as any duration longer than twelve hours, activates gluconeogenesis in order to achieve the body's ideal glucose levels.
Other glucoregulatory hormones, such as growth hormone, cortisol, glutamate, amylin, epinephrin, and glucose-dependent insulinotropic peptide (GIP), are also implicated in glucose circulatory processes in addition to insulin and glucagon.

These glucoregulatory hormones are necessary to maintain an optimal rate of glucose circulation in body, especially during fasting periods where there is constant outflux of glucose from cells and tissues.

While it has been noted that the liver makes a substantial contribution to the systemic glucose pools, in severe cases of starvation, the kidneys and livers are the only organs that produce the enzyme that releases glucose into the bloodstream—the glucose-6-phosphatase hormone—so even though tissues are capable of hydrolysing glycogen stores, the body still depends on these two organs for this enzyme.

Under a bi-hormonal model of glucose homeostasis, insulin and glucagon are the main drivers of glucose disappearance and appearance in systemic pools, respectively. Blood glucose levels then drop during mid-postprandial states, which precipitates a fasting phase lasting several hours until the next feeding period. Insulin drives glucose influx to skeletal muscles and adipose tissue during immediate postprandial states, while also suppressing further glucose production throughendogenous channels. Insulin regulation further suppresses glucagon production to stop glucose influx in blood streams.

2 Depression's Effect on Diabetes Management

What impact does melancholy have on diabetes patients' compliance with medication and lifestyle changes?

Anyone can experience depression, also known as depressive disorder, which is a prevalent mental health problem. It

is typified by a persistently depressed mood, a loss of enjoyment, or disinterest in activities.

This isn't the same as your typical mood swings or thoughts about daily living. For at least two weeks, the majority of the day, almost every day, is spent in depressive episodes. Sleep disturbances and eating abnormalities are common in people with depression. They could experience pessimism for the future, thoughts of death, and poor self-worth. Exhaustion and difficulty focusing are also frequent.

A complex interplay of biological, psychological, and social elements leads to depression. Individuals who have experienced abuse, significant losses, or other unfavourable situations are more susceptible to depression. Depression can also be brought on by issues at work or school.

It has been demonstrated that preventative initiatives lessen depression. Effective pharmacological and psychosocial therapies are also available for depression.

Patients with diabetes may experience substantial difficulties adhering to treatment regimens and changing their lifestyles due to depression. Individuals with depression symptoms may find it more difficult to successfully manage their diabetes, which might have a negative impact on medication adherence as well as decreased adherence to lifestyle adjustments. Specifically, compared to people without depression, diabetes patients with depression may adhere to lifestyle changes less consistently. Furthermore, sadness may lead to a decrease in the adoption of other diabetes control practices, such as medication, exercise, diet, and glucose monitoring. Depressed diabetic individuals may adhere to their therapy less closely, which might be linked to changes in glucose control.

Patients with depression who simultaneously have deteriorating glycemic control may need medical services more frequently. The purpose of the study was to determine whether diabetes management practices and depression status are related. It was discovered that individuals with depression have a positive correlation with HbA1c tests, but that theseverity of their depressive symptoms is linked to poorer adherence to diet type and quantity as well as the use of oral hypoglycemics. Additionally, compared to non-depressed individuals, depressed patients have higher levels of insulin resistance following oral glucose testing. When depression appears, adopting diabetes management practices and maintaining disease control may become more difficult. In order to satisfy patients' needs and maximise outcomes in a proactive manner, the American Diabetes Association advises periodic mental health exams like Mental Status Examination (MSE), etc.

3 How do diabetes and depression interact clinically?

Diabetes and depression are clinically related in a number of ways:

Biological Factors: Both disorders may be associated with abnormalities in neurotransmitters, including serotonin, which is involved in mood regulation. In diabetics, alterations in neurotransmitter levels may have a role in the onset or exacerbation of depression.

Psychological Impact: Managing diabetes can be difficult as it involves food restrictions, lifestyle modifications, regular blood sugar testing, and adherence to insulin or medication regimes. Anxiety and despair may be exacerbated by the strain and stress of treating a chronic condition.

Bidirectional Relationship: Depression can both worsen the prognosis for those who already have type 2 diabetes and raise the risk of the disease. On the other hand, because of the strain of treating the illness, anxiety about complications, and the effects of diabetes-related health problems, having diabetes can raise the likelihood of developing depression.

Inflammation and Immune System: Prolonged inflammation has been linked to depression and diabetes, suggesting that these two illnesses are related. An essential component of type 2 diabetes, insulin resistance, can arise as a result of inflammation, which can also impact insulin sensitivity. It may also have an effect on mood control and exacerbate the symptoms of depression.

Lifestyle Factors: Poor eating habits, inactivity, smoking, and binge drinking are among the unhealthy lifestyle choices that increase the risk of type 2 diabetes and depression. Both diseases can benefit from addressing these lifestyle variables via support, counselling, and education.

Social and Economic variables: Higher incidence of diabetes and depression can be attributed to socioeconomic variables such as social isolation, restricted access to healthcare, and poorer income. It may be crucial to address socioeconomic determinants of health in order to manage and prevent both illnesses.

4 What emotional and psychological difficulties do individuals with diabetes who also have depression face?

Patients with diabetes who also have depression may encounter significant psychological and emotional difficulties. For some people, regulating diabetes can be burdensome, as depression can make it difficult to make decisions. Diagnosing depression in individuals with diabetes can be difficult, and discussing feelings of sadness or despair can be difficult for these patients as well. Diabetic distress is a syndrome that patients may suffer that can lead to emotions

of helplessness and despair.

In addition, symptoms like sadness may arise from inadequate management of diabetes. Patients who also suffer from anxiety or depression may experience comparable difficulties. Excessive or low blood sugar levels can result in elevated emotions of anxiousness, restlessness, or low energy. Low blood sugar can produce shakiness and sweating, among other symptoms comparable to anxiety. It is important to discuss any concerns you have about your mental health with the doctor. A physician who specialises in diabetes care and has expertise of mental health issues can assist in treating co-occurring depression. It might be difficult but not impossible to diagnose and treat depression in diabetes people. Patients with type 1 and type 2 diabetes mellitus may experience reduced quality of life as a result of psychiatric problems and symptoms.

As a result, managing diabetic discomfort is essential to managing diabetes overall. Patients with diabetes who are experiencing mental health problems can get support, and it's critical to get care when you need it.

5 What are some possible treatments to address the way depression affects diabetes patients' quality of life decline?

Diabetes patients frequently co-occur with depression, which is frequently underdiagnosed. In actuality, approximately 25% to 50% of diabetic patients with depression receive a thorough diagnosis, and the frequency of depression in persons with diabetes is two to three times greater than in people without the disease. Depression has been associated with greater risks of diabetic complications, increased disability, and reduced life expectancy. This is due to the fact that melancholy may make patients disregard their diabetic self- management practices, which include frequent exercise, stopping smoking, and self-checking blood glucose levels. Depression may sometimes further worsen the signs and indicators of diabetes therefore make treatment more challenging.

Furthermore, comorbid depression may result in worse results and an increased risk of complications because the patient manages their diabetes 95% of the time. Nonetheless, it is possible to put into practice efficient strategies that deal with managing depression and diabetes. Research has indicated that improving glucose control and diabetic self-care practices can result from treating depression.

Additionally, people with depression who receive therapy report being better able to take care of themselves and feeling more capable of managing the effects of their diabetes.

Therefore, treating comorbid depression in people with diabetes is essential to enhancing their quality of life and general health outcomes.

The current study highlights how depression significantly impairs diabetes patients' ability to adhere to treatment plans and lifestyle changes. The study emphasises how crucial it is to identify and treat depression in diabetic patients in order to properly control the disease overall. The study's conclusions imply that, in comparison to diabetes patients without depression, people with depression may adhere to medication and lifestyle changes less closely. Depression symptoms can make it difficult for people to properly manage their diabetes, which can have a poor impact on medication adherence and decrease adherence to lifestyle adjustments. The study report goes on to say that

depression might decrease glucose management, which can lead to greater medical use.

6. Pathophysiological processes underlying depression and diabetes.

Dysfunction of the Hypothalamic-Pituitary-Adrenal (HPA) Axis: The HPA axis is a multifaceted system that plays a role in the body's reaction to stress. Dysregulation of the HPA axis can result in aberrant cortisol levels and a stress response in both diabetes and depression. Prolonged stress and disruption of the hypothalamus-pituitary axis can exacerbate symptoms of depression and impair diabetic metabolic homeostasis.

Oxidative Stress: Depression and diabetes are associated with increased oxidative stress, which is defined as an imbalance between antioxidants and reactive oxygen species. Inflammation and cellular damage are two outcomes of oxidative stress that contribute to the pathophysiology of both illnesses.

Neuroendocrine dysregulation: Hormones that are important for energy metabolism, appetite control, and mood include insulin, leptin, and ghrelin. Both diabetes and depression are associated with hormone dysregulation, which can lead to mood swings and metabolic problems.

Mitochondrial Dysfunction: Cells produce energy through the activity of their mitochondria. Diabetes and depression are linked to mitochondrial dysfunction, which impairs energy metabolism, increases oxidative stress, and modifies neurotransmitter signalling.

Genetic and Environmental Factors: There are genetic predispositions for both depression and diabetes, and specific genetic variations may make both disorders more likely to develop.

Environmental aspects like nutrition, exercise, sleep habits, and stress exposure are also important in the pathophysiology of depression and diabetes.

Neurotransmitter Imbalance: Changes in the brain's neurotransmitter levels can be a factor in both depression and diabetes. Neurotransmitters important in mood modulation, such as norepinephrine, dopamine, and serotonin, are frequently reduced in depression. Changes in blood glucose levels in diabetics can also affect neurotransmitter activity, which can lead to mood swings.

Inflammation: Depression and diabetes are both associated with persistently low-grade inflammation. Increased production of inflammatory cytokines can result from insulin resistance and hyperglycemia in individuals with diabetes. In a similar vein, higher indicators of inflammation have been linked to depression. This inflammatory reaction has the potential to impair brain function and have a role in the onset or aggravation of depression symptoms in diabetics.

7. Study Location and Population

The control group consisted of human participants in good health who could give informed permission and were between the ages of 18 and 65. Cases were defined as T2DM patients who were ≥18 years old and ≤65 years old, who had the capacity to give informed consent.

Excluded from consideration were cases with type 1 diabetes, severe mental illnesses (such as alcoholism, severe depression, schizophrenia, bipolar disorder), individuals already taking psychotropic medications, severe diabetes complications (such as amputation, blindness, renal insufficiency, and dialysis), liver disease, renal disease, primary hyperparathyroidism, cancer, HIV, obesity, congestive heart failure, myocardial infarction, coronary artery bypass surgery, or percutaneous coronary intervention within the preceding six months), cardiac arrhythmias, and inability or unwillingness to provide written informed consent were all excluded.

Sample size and technique of sampling.

Eighty participants were the expected sample size for this investigation. The sample size was determined based on the following assumptions: a 95% confidence level, a 5% margin of error, and a 50% prevalence of depression among diabetes patients. The 95% confidence interval (95%CI) obtained from the normal distribution has a value of 1.96. To make things more manageable, we rounded it to 2. The study included all type-2 diabetic patients who visited the diabetes clinic, satisfied the inclusion criteria, and expressed a willingness to participate.

Surveys: Two standardised questionnaires were used during "face-to-face" interviews to gather the data. The Diabetes-Dependent Quality of Life (ADDQoL) and the Patient Health Questionnaire-9 (PHQ-9).

Evaluation of depression: Depression in individuals with diabetes who also had depression and control patients was measured using the PHQ-9 questionnaire. A categorization method for the 257 is provided by the PHQ-9. Depression and inflammation in type 2 diabetes are associated with the diagnosis of depression. Depressed mood or anhedonia is one of the symptoms of major depression, which is diagnosed if five or more of the nine depressive symptom criteria were present for at least "more than half the days" in the preceding two weeks (suicidal thoughts count if present at all).

Furthermore, the aggregate score [0–27] was employed for screening and depression severity assessment. A cumulative score of 10 or greater is the cut-off mark that is most frequently used to signify a positive case for depressive illness.

Evaluation of living quality: QoL was evaluated in several situations using the ADDQoL questionnaire. The 19-item ADDQoL measures how certain elements of living are affected by diabetes and how important these factors are to

quality of life. Since this is a "individualised" metric, not every item is presumed to be applicable to every person: Five things, such as working life, have a basic "Yes/No" choice.

The analyses were conducted using a full core data set of 80 people with T2DM and controls that included age, sex, body mass index (BMI), and length of diabetes. For continuous or categorical variables, data are shown as the standard deviation (SD) or percentage (%). Fisher's exact test and the student's t-test (two-sided) were used to examine the differences between controls and cases. Unpaired t-tests or nonparametric tests (two-sided correlation) were used to determine unadjusted correlations between biomarkers of subclinical inflammation and/or depression scores, along with the accompanying p-value; $p<0.05$.

Therapies available for depression and Diabetes Mellitus

For depression, there are several therapies that fall into two general categories: medication-based treatments and psychotherapy.

Cognitive behavioural therapy (CBT) is a form of talk therapy used in psychotherapy that focuses on recognising and altering depressive-related negative thinking patterns and behaviours. It supports the growth of coping mechanisms and problem-solving abilities in people.

The goal of interpersonal therapy, or IPT, is to enhance communication and interpersonal interactions. It lessens feelings of loneliness, enhances social support, and assists people in addressing and resolving disputes.

Psychodynamic therapy: This type of treatment looks at underlying emotions and ideas that might lead to depression. It looks for underlying tensions and patterns that affect behaviour and mood. Therapies based on mindfulness, such as Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR), use mindfulness techniques to help patients become more conscious of their thoughts and feelings, which lowers reactivity and enhances mood regulation.

Treatments Based on Medication:

Antidepressants: These drugs, which are often recommended for depression, elevate mood by changing the chemistry of the brain. Tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) are some of the antidepressant types.

Mood Stabilisers: Lithium is one such mood stabiliser that may be administered sometimes, particularly for bipolar depression.

Antipsychotics: When psychotic symptoms are present or there is severe depression, these drugs may be used in addition to antidepressants.

Stimulants: To increase energy and elevate mood in patients with treatment-resistant depression, stimulant medicines may be taken into consideration.

Additional Interventions and Therapies:

Electrical currents are sent into the brain during electroconvulsive therapy (ECT) in order to cause controlled seizures. It is mostly used for severe depression for which no other medication has worked.

Transcranial Magnetic Stimulation (TMS): TMS stimulates brain nerve cells by applying magnetic fields. It is a non-invasive method for treating depression that is resistant to therapy.

Exercise and Lifestyle Modifications: A healthy diet, regular exercise, enough sleep, and stress reduction strategies can all help manage depression.

Collaborative therapy for depression and diabetes mellitus

Diabetes mellitus and depression are treated together with an integrated strategy in collaborative treatment. Given the substantial influence depression may have on diabetes control and vice versa, it is imperative to develop a comprehensive treatment strategy that considers the interaction between mental and physical health.

Integrated Care Teams: A multidisciplinary team of medical specialists, such as primary care physicians, endocrinologists, psychiatrists or psychologists, diabetes educators, and nutritionists, are frequently involved in collaborative therapy. Together, this team evaluates and treats diabetes and depression's emotional as well as physical components.

Holistic Assessment: A comprehensive evaluation is carried out to analyse the person's mental and physical health (e.g., symptoms of depression, anxiety, stresses).

Education and Self-Management: Patients get education on the connection between depression and diabetes, the ways in which each illness might impact the other, and the significance of taking care of oneself and following treatment regimens. This covers diabetic self-management techniques include blood sugar monitoring, taking prescription drugs as prescribed, maintaining a balanced diet, and engaging in regular exercise.

Behavioural Interventions: To address depressive symptoms, negative thought patterns, coping mechanisms, and stress management approaches, the treatment plan incorporates Cognitive Behavioural Therapy (CBT) and other evidence-based psychotherapies. Behavioural therapies might also focus on lifestyle modifications to enhance the management of diabetes.

Medication Management: Healthcare professionals collaborate to offer medication management for patients with co-occurring depression and diabetes. When recommended, antidepressants are picked carefully to minimise drug interactions with diabetes treatments and to treat mood disorders as well as possible blood sugar-related side effects.

Support Groups & Peer Support: Participating in peer support programmes or support groups designed especially for people with diabetes and depression can offer a feeling of community, encouragement, and emotional support. It may be empowering to share coping mechanisms and experiences with those who are going through comparable difficulties.

Frequent Follow-Up and Monitoring: Collaborative therapy involves routine follow-up meetings to assess progress, make necessary plan adjustments, and deal with any obstacles or difficulties that may come up. People may maintain their motivation and commitment to their health objectives with the aid of this continual support.

In order to manage diabetes and depression concurrently, collaborative therapy emphasises a personalised and comprehensive approach, acknowledging the intricate relationships that exist between physical health, mental health, and quality of life. It seeks to raise self-efficacy, advance general wellbeing, and improve results.

Depression treatment using psychosocial therapy.

A variety of treatment modalities that concentrate on treating the psychological and social aspects that contribute to depression are included in psychosocial therapy for depression. These treatments seek to raise general well-being, strengthen coping mechanisms, and elevate mood. The following are important categories of psychosocial treatments for depression:

Cognitive behavioural therapy, or CBT, is an extensively utilised and scientifically supported
treatment for depression. It focuses on recognising and combating unfavourable mental patterns and attitudes that exacerbate symptoms of depression. Through cognitive behavioural therapy (CBT), people can learn how to reframe negative thoughts, create more flexible coping mechanisms, and activate their behaviour in order to feel happier and more upbeat.

Interpersonal Therapy (IPT): The foundation of IPT is the idea that relationship problems and interpersonal disputes may be linked to depression. The goals of this treatment are to strengthen social support networks, resolve interpersonal issues, and improve communication skills. IPT frequently concentrates on particular interpersonal problems including bereavement, changing roles, conflict between people, and social isolation.

Interpersonal Therapy (IPT): The foundation of IPT is the idea that relationship problems and interpersonal disputes may be linked to depression. The goals of this treatment are to strengthen social support networks, resolve interpersonal issues, and improve communication skills. IPT frequently concentrates on particular interpersonal problems including bereavement, changing roles, conflict between people, and social isolation.

Therapies Based on Mindfulness: Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness- Based Stress Reduction (MBSR) are two examples of mindfulness-based treatments that combine cognitive and behavioural strategies with mindfulness practices. Through these therapies, people can learn to better control their thoughts and emotions, lessen ruminating, successfully manage stress, and develop an attitude of non-judgment towards their

experiences.

Behavioural Activation (BA): BA is a behavioural treatment that aims to reduce depression by boosting participation in fulfilling and meaningful activities. It entails choosing and planning fun, goal-oriented activities, establishing realistic objectives, and keeping track of advancements. The goal of BA is to combat the lethargy and withdrawal that are frequently connected to depression.

Supportive Therapy: This type of therapy offers a compassionate and secure setting in which people may talk about their struggles, express their emotions, and get support and affirmation. Supportive therapy can be helpful in providing emotional support, developing rapport, and establishing a therapeutic relationship even if it might not be as organised as other therapies.

Problem-Solving treatment (PST): PST is a goal-oriented, organised treatment that teaches people how to solve problems effectively so they can deal with pressures and challenges in their lives.

Psychosocial Therapy (PST) facilitates the development of resilience and enhances coping skills in individuals by decomposing difficulties into feasible stages, coming up with alternate solutions, and carrying out action plans.

Group Therapy: In a safe and encouraging environment, group therapy allows people who are depressed to communicate, encourage one another, and acquire coping mechanisms. Enhancing social connectivity, lowering feelings of loneliness, and giving a sense of belonging are all possible with group therapy.

Depending on the severity and unique requirements of the patient, these psychosocial treatments may be utilised either alone or in conjunction with medicine. They are usually customised to meet the specific needs and objectives of each individual and are provided by licenced mental health experts like psychologists, counsellors, or therapists.

Pharmacotherapies for depression and diabetes

Pharmacotherapy is the use of drugs to treat diabetes and depression in order to properly control both disorders.

Depression pharmacotherapy: Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs are a family of antidepressant drugs that function by raising serotonin levels in the brain. Examples include paroxetine (Paxil), escitalopram (Lexapro), sertraline (Zoloft), and fluoxetine (Prozac). Because of their efficiency and very minimal side effect profile, SSRIs are frequently regarded as the first line of therapy for depression.

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): SNRIs raise serotonin and norepinephrine levels. Examples of SNRIs are venlafaxine (Effexor) and duloxetine (Cymbalta). They could be administered to people who have anxiety symptoms in addition to not responding well to SSRIs. Tricyclic Antidepressants (TCAs): TCAs are older antidepressants that function by raising serotonin and norepinephrine levels. Examples of TCAs are amitriptyline (Elavil) and nortriptyline (Pamelor). Despite having more negative effects than other drugs, they are occasionally used when none of the others work.

Another family of antidepressants known as monoamine oxidase inhibitors (MAOIs) includes tranylcypromine (Parnate) and phenelzine (Nardil). MAOIs function by blocking the enzyme monoamine oxidase. Because they can have

major interactions with some foods and other drugs, they are not as commonly used as other antidepressants.

Atypical antidepressants: Unlike SSRIs and SNRIs, these drugs work differently, and examples of such drugs are bupropion (Wellbutrin) and mirtazapine (Remeron). When other antidepressants are ineffective or when certain effects, including appetite loss or sleeplessness, are severe, they may be used.

Diabetes Pharmacotherapy: Oral Antidiabetic Drugs: People with type 2 diabetes can take these drugs to reduce their blood sugar levels. Among these are metformin, sulfonylureas (glipizide, glyburide), meglitinides (repaglinide), inhibitors of dipeptidyl peptidase-4 (DPP-4) (sitagliptin, saxagliptin), and inhibitors of sodium-glucose cotransporter-2 (SGLT2) (e.g., empagliflozin, dapagliflozin).

Insulin Therapy: When oral drugs are insufficient for managing blood sugar levels in people with type 1 diabetes or in certain circumstances, type 2 diabetes, insulin is utilised. There are several forms of insulin that are available, such as formulations that are long-acting, intermediate-acting, short- acting, and rapid-acting.

GLP-1 Receptor Agonists: These drugs, which include dulaglutide (Trulicity) and liraglutide (Victoza), increase the release of insulin and lower blood sugar. They are frequently used with other diabetic medicines.

Insulin Sensitizers: Drugs that increase the body's sensitivity to insulin, such as rosiglitazone (Avandia) and pioglitazone (Actos), can also assist reduce blood sugar levels.

Combination Therapies: To obtain the best blood sugar control, some people may need combination therapy involving insulin plus oral medicines or many antidiabetic drugs.

8. Discussion

It is believed that neurotransmitters, which influence mood and behaviour, are the underlying cause of depression. Depression and physiological alterations in the neuroendocrine system are associated.

It is thought that psychological stress activates counter-regulatory hormones such glucagon, growth hormone, glucocorticoids, and catecholamines. The normal action of insulin is hindered by the activation of counter-regulatory hormones, which causes insulin to elevate blood glucose instead of lowering it. A rise in glucose levels makes it extremely difficult to maintain metabolic regulation.

Depression may be brought on by or made worse by poor glucose management and functional impairment brought on by an increase in diabetes complications.

Diabetes self-care practices, including as taking medications as prescribed, keeping an eye on blood sugar levels, eating a balanced diet, and exercising frequently, might be hampered by depression. Poor glycemic control, a higher risk of complications from diabetes, and a larger chance of hospitalisations can result from this.

Depression symptoms have been linked to a higher chance of experiencing complications from diabetes, including nephropathy, neuropathy, retinopathy, and cardiovascular disease.

Inflammation, insulin resistance, and other pathophysiological processes that underlie these issues can all be made worse by depression.

Depression in diabetes patients is linked to a lower standard of living, which includes limits in everyday activities, worse self-esteem, impaired social functioning, and decreased productivity. Depression and diabetes together have

the potential to create a vicious cycle of deteriorating mental and physical health.

Compared to either illness alone, having diabetes and depression together is linked to a greater death risk. Diabetes patients with depression had a higher chance of dying young, which emphasises the need of mental health in diabetes treatment.

Patients with diabetes who also have comorbid depression frequently need extra medical services, such as regular check-ups, hospital stays, and specialised mental health treatment. This can affect access to prompt and thorough care and exerts a heavy financial strain on healthcare systems.

Coping with depression and diabetes can have a significant psychological impact. Patients may struggle to manage the responsibilities of treating many chronic illnesses at the same time, as well as feelings of stigma, loneliness, and fear about the future.

Psychiatric drugs and diabetes therapies may interact, and managing depression in diabetic patients can be difficult because of these factors as well as worries about weight gain and other adverse

effects. For the best results, integrated care strategies that meet the requirements of both mental and physical health are crucial.

Numerous research' worth of data repeatedly demonstrate how depression negatively affects diabetes patients' health results. Managing depression well is essential for diabetics if they want to improve their overall prognosis, adherence to medication, and quality of life. Diabetes patients who have depression can benefit greatly from the screening, counselling, and appropriate referral to mental health professionals provided by healthcare providers.

Results

It was clear that some characteristics, such as higher income, not using insulin, better glycaemic control, and older age, were associated with improved diabetes-specific quality of life. But having a cancer diagnosis and being single were also linked to improved ADDQoL. Furthermore, there was a high correlation between the existence of diabetes problems and mental health issues such depression, anxiety, and schizophrenia and a lower quality of life that was specifically related to diabetes. Even after controlling for age, gender, length of diabetes, type of therapy, sample location, and other therapeutic and sociodemographic factors, these correlations remained.

Conclusion

Depression is common in both types 1 and 2 diabetes and has a significant role on the course and outcome of this medical illness. In a primary care population, diabetes self-care was suboptimal across a continuation from home-based activities, such as healthy eating, workout, and medication adherence, to use of preventive care. Major depression was chiefly associated with patient-initiated behaviors that are not easy to support (e.g., exercise, diet, and medication adherence) but not with preventive services for diabetes. Depression is a matter of great concern in patients with DM. It is not only highly accepted, but also highly persistent and recurrent causing a significant negative impact on both clinical outcomes and QOL. Besides, impaired QOL, it further deteriorates clinical outcomes and has been prospective leads to increased mortality in DM. Frequency of primary care visits (≥7), female gender, poor self-rated physical

health, panic attacks, and dysthymia were agents independently associated with increased probability for correct

depression recognition. Cuming to the management of depression in DM, psychotherapy combined with psychoeducational interventions or collaborative care seem to be cost-effective and yield beneficial and good results, both on mental health outcomes as well as diabetes management and glycemic control.

References

1. Mental health issues decrease diabetes-specific quality of life independent of glycaemic control and complications: findings from Australia's living with diabetes cohort study
https://doi.org/10.1186/1477-7525-11-170

2. **A COMPREHENSIVE REVIEW ON DEPRESSION IN DIABETIC PATIENTS**
https://doi.org/10.22159/ajpcr.2017.v10i7.18465

3. Ma Q, Li Y, Wang M, Tang Z, Wang T, Liu C, et al. Progress in metabonomics of type 2 Diabetes Mellitus. Molecules. 2018 Jul;23(7):1834. https://doi.org/10.3390/molecules23071834

4. Lushchak O, Zayachkivska A, Vaiserman A. Metallic nanoantioxidants as potential therapeutics for type 2 diabetes: a hypothetical background and translational perspectives. Oxid Med Cell Longev. 2018 Jun; 2018:1-9. https://doi.org/10.1155/2018/3407375

5. AlMansariA,ObeidY,IslamN,FariduddinM,HassounA,DjabalahK,etal.GOAL study:clinicalandnon-clinicalpredictivefactors forachievingglycemiccontrolinpeoplewithtype2diabetesinrealclinicalpractice.BMJOpenDiabetesResCare.2018 Jul;6(1):e000519. https://doi.org/10.1136/bmjdrc-2018-000519

6. Albasheer OB, Mahfouz MS, Solan Y, Khan DA, Muqri MA, Almutairi HA, et al. Depression and related risk factors among patients with type 2 diabetes mellitus, Jazan area, KSA: A cross-sectional study. Diabetes Metab Syndr Clin Res Rev. 2018 Apr;12(2):117 -21. https://doi.org/10.1016/j.dsx.2017.09.014

7. Hemmy Asamsama O, Lee JW, Morton KR, Tonstad S. Bidirectional longitudinal study of type 2 diabetes and depression symptoms in black and white church going adults. J Diabetes Metab Disord. 2015 Dec;14(1):25. https://doi.org/10.1186/s40200-015-0150-5

8. Xia W, Luo Y, Chen Y-C, Zhang D, Bo F, Zhou P, et al. Disrupted functional connectivity of the amygdala is associated with depressive mood in type 2 diabetes patients. J Affect Disord. 2018 Mar; 228:207-15. https://doi.org/10.1016/j.jad.2017.12.012

9. Mendenhall E, Norris SA, Shidhaye R, Prabhakaran D. Depression and type 2 diabetes in low- and middle-income countries: A systematic review. Diabetes Res Clin Pract. 2014 Feb;103(2):276-85.

https://doi.org/10.1016/j.diabres.2014.01.001

10. Increased serum interleukin-9 and interleukin-1β are associated with depression in type 2 diabetes patients.
Rizwana PARVEEN, Mohd Ashif KHAN, Sunil KOHLI, Nidhi B. AGARWAL, Prabhat Varshney

https://www.researchgate.net/publication/341793009_Increased_serum_interleukin-9_and_interleukin-1b_are_associated_with_depression_in_type_2_diabetes_patients

11. LaakeJ-PS,StahlD,AmielSA,PetrakF,SherwoodRA,PickupJC,etal.The Associationbetweendepressivesymptomsandsystemicinflammationin peoplewithtype2diabetes:findingsfromtheSouthLondonDiabetesStudy. DiabetesCare.2014Aug;37(8):2186-92. https://doi.org/10.2337/dc13-2522

12. Herder C, Schmitt A, Budden F, Reimer A, Kulzer B, Roden M, et al. Association between pro- and anti-inflammatory cytokines and depressive symptoms in patients with diabetes—potential differences by diabetes type and depression scores. Transl Psychiatry. 2017 Nov;7(11). https://doi.org/10.1038/s41398-017-0009-2

13. Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci. 2002 Mar;4(1):7-20.

14. Habibi L, Tafakhori A, Hadiani R, Maserat-Mashhadi M, Kafrash Z, Torabi S, et al. Molecular changes in obese and depressive patients are similar to neurodegenerative disorders. Iran J Neurol. 2017 Oct;16(4):192-200.

15. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry. 2011 Jul;16(7):751-62. https://doi.org/10.1038/mp.2010.52

16. Karlsson L , Nousiainen N, Scheinin NM, Maksimow M, Salmi M, Lehto SM, et al. Cytokine profile and maternal depression and anxiety symptoms in mid-pregnancy—the FinnBrain Birth Cohort Study. Arch Womens Ment Health. 2017 Feb;20(1):39-48. https://doi. org/10.1007/s00737-016-0672-y

17. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606- https://doi.org/10.1046/j.1525-1497.2001.016009606.x

18. Sweileh WM, Abu-Hadeed HM, Al-Jabi SW, Zyoud SH. Prevalence of depression among people with type 2 diabetes mellitus: a cross sectional study in Palestine. BMC Public Health. 2014 Dec;14(1):163. https://doi.org/10.1186/1471-2458-14-163

20. van den Biggelaar AHJ, Gussekloo J, de Craen AJM, Frölich M, Stek ML, van der Mast RC, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol. 2007 Jul;42(7):693-701. https://doi.org/10.1016/j.exger.2007.01.011